Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles

Biomaterials

Volumn 35, Issue 31, 2014, Pages 8854-8866

  Gao, Fuping ^a   Yuan, Qing ^a   Gao, Liang ^a   Cai, Pengju ^b   Zhu, Huarui ^a   Liu, Ru ^a   Wang, Yaling ^a   Wei, Yueteng ^a   Huang, Guodong ^b   Liang, Jian ^b   Gao, Xueyun ^a  

^a INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^b RUIKANG HOSPITAL AFFILIATED TO GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antitumor drug; Apoptosis; Nrf2 ARE pathway; Selenium nanoparticle; Toxicity

Indexed keywords

BIOCHEMISTRY; CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; HISTOLOGY; NANOPARTICLES; SELENIUM; TOXICITY; TUMORS;

ANTIOXIDANT RESPONSIVE ELEMENTS; ANTITUMOR DRUGS; CHEMOTHERAPEUTIC DRUGS; IN-VIVO EXPERIMENTS; NRF2-ARE PATHWAY; SELENIUM NANOPARTICLES; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; CASPASE 7; CASPASE 8; CASPASE 9; IRINOTECAN; NANOPARTICLE; PEROXIREDOXIN 1; PROTEIN P53; SELENIUM NANOPARTICLE; THIOREDOXIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CAMPTOTHECIN; SELENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THERAPY EFFECT; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; FEMALE; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS; RATS; SELENIUM;

EID: 84905456593     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.004     Document Type: Article

References (56)

1. Lheureux S., Clarisse B., Launay-Vacher V., Gunzer K., Delcambre-Lair C., Bouhier-Leporrier K., et al. Evaluation of current practice: management of chemotherapy-related toxicities. Anti-Cancer Drug 2011, 22:919-925.
2. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356:233-241.
3. Rayman M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005, 64:527-542.
4. Zeng H.W., Combs G.F. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 2008, 19:1-7.
5. Lu J.X., Jiang C. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 2005, 7:1715-1727.
6. Yazdi M.H., Mahdavi M., Kheradmand E., Shahverdi A.R. The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittelforschung 2012, 62:525-531.
7. Klein E.A. Selenium: epidemiology and basic science. J Urol 2004, 171:S50-S53. [discussion S53].
8. Whanger P.D. Selenium and its relationship to cancer: an update. Br J Nutr 2004, 91:11-28.
9. Meyer F., Galan P., Douville P., Bairati I., Kegle P., Bertrais S., et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005, 116:182-186.
10. Amaral A.F.S., Cantor K.P., Silverman D.T., Malats N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers 2010, 19:2407-2415.
11. Combs G.F. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr 2005, 135:343-347.
12. Chen Y.C., Prabhu K.S., Mastro A.M. Is selenium a potential treatment for cancer metastasis?. Nutrients 2013, 5:1149-1168.
13. Zeng H.W., Cheng W.H., Johnson L.K. Methylselenol, a selenium metabolite, modulates p53 pathway and inhibits the growth of colon cancer xenografts in Balb/c mice. J Nutr Biochem 2013, 24:776-780.
14. Kong L., Yuan Q., Zhu H., Li Y., Guo Q., Wang Q., et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 2011, 32:6515-6522.
15. Brigelius-Flohe R. Selenium compounds and selenoproteins in cancer. Chem Biodivers 2008, 5:389-395.
16. Bi X.L., Pohl N., Dong H.L., Yang W.C. Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol 2013, 6:8.
17. Cao S.S., Durrani A., Rustum Y.M. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004, 10:2561-2569.
18. Li Z.S., Carrier L., Belame A., Thiyagarajah A., Salvo V.A., Burow M.E., et al. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. Breast Cancer Res Treat 2009, 118:33-43.
19. Umysova D., Vitova M., Douskova I., Bisova K., Hlavova M., Cizkova M., et al. Bioaccumulation and toxicity of selenium compounds in the green alga Scenedesmus quadricauda. BMC Plant Biol 2009, 9.
20. Tarze A., Dauplais M., Grigoras I., Lazard M., Ha-Duong N.T., Barbier F., et al. Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae. J Biol Chem 2007, 282:8759-8767.
21. Zhang J.S., Wang H.L., Yan X.X., Zhang L.D. Comparison of short-term toxicity between Nano-Se and selenite in mice. Life Sci 2005, 76:1099-1109.
22. Wycherly B.J., Moak M.A., Christensen M.J. High dietary intake of sodium selenite induces oxidative DNA damage in rat liver. Nutr Cancer 2004, 48:78-83.
23. Peng D., Zhang J., Liu Q., Taylor E.W. Size effect of elemental selenium nanoparticles (Nano-Se) at supranutritional levels on selenium accumulation and glutathione S-transferase activity. J Inorg Biochem 2007, 101:1457-1463.
24. Wang H.L., Zhang J.S., Yu H.Q. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. Free Radic Biol Med 2007, 42:1524-1533.
25. Jia X., Li N., Chen J. A subchronic toxicity study of elemental Nano-Se in Sprague-Dawley rats. Life Sci 2005, 76:1989-2003.
26. Zhang J.S., Gao X.Y., Zhang L.D., Bao Y.P. Biological effects of a nano red elemental selenium. Biofactors 2001, 15:27-38.
27. Zhang J.S., Wang X.F., Xu T.W. Elemental selenium at nano size (Nano-Se) as a potential chemopreventive agent with reduced risk of selenium toxicity: comparison with Se-methylselenocysteine in mice. Toxicol Sci 2008, 101:22-31.
28. Zhou X.X., Wang Y.B., Gu Q., Li W.F. Effects of different dietary selenium sources (selenium nanoparticle and selenomethionine) on growth performance, muscle composition and glutathione peroxidase enzyme activity of crucian carp (Carassius auratus gibelio). Aquaculture 2009, 291:78-81.
29. Hare J.I., Neijzen R.W., Anantha M., Dos Santos N., Harasym N., Webb M.S., et al. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C) and 5-fluorouracil. PloS One 2013, 8:e62349.
30. Teicher B.A., Andrews P.A. Anticancer drug development guide: preclinical screening, clinical trials, and approval 2004, Totowa, New Jersey. 2nd ed.
31. Figg W.D., Mcleod H.L. Handbook of anticancer pharmacokinetics and pharmacodynamics 2004, Totowa, New Jersey. 2nd ed.
32. Xu J.M., Wang Y., Ge F.J., Lin L., Liu Z.Y., Sharma M.R. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. World J Gastroenterol 2013, 19:3899-3903.
33. Anthony L. Irinotecan toxicity. Curr Opin Support Palliat Care 2007, 1:35-39.
34. Meulmeester E., Jochemsen A.G. p53: a guide to apoptosis. Curr Cancer Drug Targets 2008, 8:87-97.
35. Lee S.W., Lee M.H., Park J.H., Kang S.H., Yoo H.M., Ka S.H., et al. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J 2012, 31:4441-4452.
36. Wang Z., Jiang C., Lu J. Induction of caspase-mediated apoptosis and cell cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002, 34:113-120.
37. Zu K., Bihani T., Lin A., Park Y.M., Mori K., Ip C. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 2006, 25:546-554.
38. Fischer J.L., Mihelc E.M., Pollok K.E., Smith M.L. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 2007, 6:355-361.
39. Jung H.J., Lee J.H., Seo Y.R. Enhancement of methyl methanesulfonate-induced base excision repair in the presence of selenomethionine on p53-dependent pathway. J Med Food 2009, 12:340-344.
40. Brozmanova J., Manikova D., Vlckova V., Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch Toxicol 2010, 84:919-938.
41. Pourkhalili N., Hosseini A., Nili-Ahmadabadi A., Hassani S., Pakzad M., Baeeri M., et al. Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World J Diabetes 2011, 2:204-210.
42. Pourkhalili N., Hosseini A., Nili-Ahmadabadi A., Rahimifard M., Navaei-Nigjeh M., Hassani S., et al. Improvement of isolated rat pancreatic islets function by combination of cerium oxide nanoparticles/sodium selenite through reduction of oxidative stress. Toxicol Mech Method 2012, 22:476-482.
43. Duntas L.H. Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm Metab Res 2009, 41:443-447.
44. Miroliaee A.E., Esmaily H., Vaziri-Bami A., Baeeri M., Shahverdi A.R., Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Method 2011, 21:200-208.
45. Ryan-Harshman M., Aldoori W. The relevance of selenium to immunity, cancer, and infectious/inflammatory diseases. Can J Diet Pract Res 2005, 66:98-102.
46. Arner E.S.J., Holmgren A. The thioredoxin system in cancer - introduction to a thematic volume of seminars in cancer biology. Semin Cancer Biol 2006, 16:419.
47. Yu Y.P., Yu G.Y., Tseng G., Cieply K., Nelson J., Defrances M., et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007, 67:8043-8050.
48. Luo H.Y., Wang F.F., Bai Y., Chen T.F., Zheng W.J. Selenium nanoparticles inhibit the growth of HeLa and MDA-MB-231 cells through induction of S phase arrest. Colloid Surf B 2012, 94:304-308.
49. Wang Z., Hu H., Li G., Lee H.J., Jiang C., Kim S.H., et al. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer 2008, 122:15-24.
50. Huang Y., He L., Liu W., Fan C., Zheng W., Wong Y.S., et al. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 2013, 34:7106-7116.
51. Zhang Y., Li X., Huang Z., Zheng W., Fan C., Chen T. Enhancement of cell permeabilization apoptosis-inducing activity of selenium nanoparticles by ATP surface decoration. Nanomedicine: Nanotechnol Biol, Med 2013, 9:74-84.
52. Christensen M.J., Nartey E.T., Hada A.L., Legg R.L., Barzee B.R. High selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells. Nutr Cancer 2007, 58:197-204.
53. Kaspar J.W., Niture S.K., Jaiswal A.K. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009, 47:1304-1309.
54. Velichkova M., Hasson T. Keap1 regulates the oxidationsensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 2005, 25:4501-4513.
55. Tanito M., Agbaga M.P., Anderson R.E. Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. Free Radic Biol Med 2007, 42:1838-1850.
56. Kim Y.J., Baek S.H., Bogner P.N., Ip C., Rustum Y.M., Park Y.M., et al. Targeting the Nrf2-Prx1 pathway with selenium to enhance the efficacy and selectivity of cancer therapy. J Cancer Mol 2007, 3:37-43.